SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: Takeda Pharmaceutical Co Ltd
Filing Type: Form 13F Information Table
Reporting Period: December 31, 2024
Context: This filing discloses the equity securities held by Takeda Pharmaceutical Co Ltd as of the end of the reporting period. It is a regulatory disclosure of investment holdings, not a financial performance report.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics for Takeda Pharmaceutical Co Ltd. Form 13F filings are limited to reporting specific equity holdings and do not contain the issuer's consolidated financial statements.
Material Changes and Holdings
The filing lists the following equity positions held by Takeda. The table below summarizes the value and voting authority for each issuer:
| Issuer Name | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| HilleVax, Inc. | 13,918,680 | $6,724,000 | Discretionary |
| Ovid Therapeutics Inc. | 5,347,500 | $5,750,000 | Discretionary |
| Ovid Therapeutics Inc. | 1,664,384 | $1,781,996 | Sole |
| Equillium, Inc. | 1,368,733 | $1,824,977 | Discretionary |
| Xilio Therapeutics, Inc. | 1,416,116 | $1,475,121 | Discretionary |
| Lyell Immunopharma, Inc. | 526,923 | $823,317 | Discretionary |
| Turnstone Biologics Corp. | 447,912 | $895,824 | Discretionary |
| Shattuck Labs, Inc. | 623,899 | $515,619 | Discretionary |
| Rani Therapeutics Holdings, Inc. | 278,370 | $203,190 | Discretionary |
| American Well Corp | 563,564 | $77,733 | Discretionary |
| Third Harmonic Bio, Inc. | 379,032 | $36,835 | Discretionary |
| Standard BioTools Inc. | 28,901 | $16,515 | Discretionary |
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or contingencies regarding Takeda's operations. The document contains a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the total aggregate value of the disclosed portfolio against Takeda's quarterly financial reports to assess the significance of these holdings relative to total assets.
- Confirm the current market prices of the listed biotech and healthcare issuers to validate the reported values as of December 31, 2024.
- Review Takeda's 10-K or 20-F filings for the same period to obtain actual revenue, profit, and cash flow data, as this Form 13F does not contain them.
- Check for any subsequent filings (e.g., Form 13F-HR/A) that may amend these holdings.